Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Between the Lines

      Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from oncologists and advanced practice providers on published, peer-reviewed content.


      Talquetamab in relapsed/refractory multiple myeloma: Extended follow-up from MonumenTAL-1 and interventions for GPRC5D-related toxicities

      Talquetamab in relapsed/refractory multiple myeloma: Extended follow-up from MonumenTAL-1 and interventions for GPRC5D-related toxicities

      July 10th 2025

      Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in RCC Following an Immune Checkpoint Inhibitor The Phase 3 TiNivo-2 Study

      Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in RCC Following an Immune Checkpoint Inhibitor The Phase 3 TiNivo-2 Study

      March 24th 2025

      Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma

      Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma

      August 27th 2024

      Latest Conference Coverage

      Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs

      Safety Management With Amivantamab Plus Lazertinib in NSCLC

      Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

      Adverse Events of Menin Inhibitors in AML: What Nurses Should Know

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      259 Prospect Plains Rd, Bldg H,
      Monroe, NJ 08831

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.